An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-56136379 in Adult Participants
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Bersacapavir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 19 Jul 2021 Status changed from recruiting to discontinued.
- 19 Jan 2021 Planned End Date changed from 28 Apr 2021 to 28 Sep 2021.
- 19 Jan 2021 Planned primary completion date changed from 26 Feb 2021 to 30 Jul 2021.